News from #ASCO22 - Part 2, Gyn Cancer Oral Abstract Session

 The #ASCO22 Oral Abstract session for Gynecologic Cancers was held on June 6, 2022. 

ATHENA–MONO (GOG-3020/ENGOT-ov45) trial - Improved Progression Free Survival, OC

Oral Abstract #ASCO22 #gyncsm
Monk
HRD positive PFS 20.2 mo Ruc 9.2 placebo

ATHENA–MONO (GOG-3020/ENGOT-ov45) rucaparib monotherapy versus placebo as maintenance treatment 1st line.
HRD measured. pic.twitter.com/6SLShPA6m9

— Dee Sparacio (@womenofteal) June 6, 2022

👀 Rucaparib improved PFS 📈 in patients w/ HRD test positive #OvarianCancer (HR 0.47), in the intent to treat analysis (HR 0.52), AND in patients w/ HRD test negative #OvarianCancer (HR 0.65).
🙌 Practice-changing and confirmatory results to support #PARPI use!#gyncsm #ASCO22 pic.twitter.com/fbCtCa5unx

— Shannon Westin (@ShannonWestin) June 6, 2022

Ruxolitinib  in OC

Oral Abstracts #ASCO22 #gyncsm Landen
phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy
*interleuken 6/JAK/STAT3 pathway
*Carbo/taxol/ruxolitinib
AE anemia
14.6 mo C/T/R arm vs 11mo C/T pic.twitter.com/YmaJGGbCuL

— Dee Sparacio (@womenofteal) June 6, 2022

Bevacizumab  use in ovarian cancer clear cell carcinoma, Japanese study

Oral Abstracts #ASCO22 #gyncsm Seki
Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma
Bev approved 2013 in Japan
Bev Benefit for CCC pic.twitter.com/Ubg6qRHV8u

— Dee Sparacio (@womenofteal) June 6, 2022

Discussion of prior 3 OC studies 

Oral Abstracts #ASCO22 #gyncsm
Dr Lengyl doing a great job reviewing Niraparib, ruxolitinib , Bev studies
* Caution using niraparib in patients with no BRCA mutation
*use Ruxolitinib in maintenance setting?
*targeting VEGF pathway in CCC pic.twitter.com/9EBSJA3WU8

— Dee Sparacio (@womenofteal) June 6, 2022

There is a significant difference in survival between #ClearCell #OvarianCancer as compared to the most common subtype (high grade serous). @ErnstLengyel #ASCO22 #gyncsm pic.twitter.com/9GDAoM5YQP

— Shannon Westin (@ShannonWestin) June 6, 2022

Relacorilant in recurrent OC ,  <2 month PFS as well as OS

Oral Abstracts #ASCO22 #gyncsm
Colombo OS data phase 2 study of relacorilant, combined w/ nab-paclitaxel recurrent platinum-resistant OC.
*relacorilant, selective glucocorticoid receptor modulator
*cortisol contributes to chemo resistance
*PFS 1.5 mo benefit remained in OS 1.7 pic.twitter.com/hWyzPKlF4f

— Dee Sparacio (@womenofteal) June 6, 2022

 Trabectedin in OC, Fallopian tube cancer - No improvement in OS survival , OC

Oral Abstracts #ASCO22 #gyncsm Scambia
Randomized phase III trial on trabectedin (ET-743)vs clinician’s choice chemo in recurrent oc, PPl, or FTcancers of BRCA-mutated or BRCAness (MITO23).
*Trabectedin failed to show Improvement in OS vs std arm .
* more AE in Trabectedin arm pic.twitter.com/YRnSZGYW12

— Dee Sparacio (@womenofteal) June 6, 2022

PESCO trial P1 expansion trial Pembro,  maveropepimut-S & cyclophosphamide, OC

Oral Abstracts #ASCO22 #gyncsm
Pembrolizumab, maveropepimut-S, & low-dose cyclophosphamide in adv epithelial OC: phase 1 expansion cohort of PESCO trial.
*AE injection site reaction
* drug well tolerated
*response seen to this combo
further study needed pic.twitter.com/z7qVmcqgFR

— Dee Sparacio (@womenofteal) June 6, 2022

Discussion of prior 3 studies 

Maveropepimut-S targets Survivin protein pic.twitter.com/RrVeGLAmO8

— Don S. Dizon MD 🇬🇺 (@drdonsdizon) June 6, 2022

O'Cearbhaill reviewing Oral abstracts now #ASCO22 #gyncsm
*We need novel targets
*include patient reported outcomes
*include at time toxicity analysis
*we need new classifications for recurrent OC pic.twitter.com/khWDR6TmhB

— Dee Sparacio (@womenofteal) June 6, 2022

Keynote 826  Cervical cancer

Gyn Oral Abstracts #ASCO22 #gyncsm
Tewari
Pembrolizumab + chemotherapy in patients w/ persistent, recurrent, or met #cervical cancer: KEYNOTE-826.
*clinically meaningful OS and PFS pic.twitter.com/YSpw0g98HK

— Dee Sparacio (@womenofteal) June 6, 2022

ENGOT Cx8/GOG 3024/innovaTV 205 Cervical Cancer 

Gyn Oral Abstracts #ASCO22 #gyncsm Vergote
Tisotumab vedotin + pembrolizumab (1L) recurrent or metastatic cervical cancer ENGOT Cx8/GOG 3024/innovaTV 205.
*TV + pembro demonstrated encouraging, durable antitumor activity with a manageable and acceptable safety profile pic.twitter.com/hWaEdVMak9

— Dee Sparacio (@womenofteal) June 6, 2022

Covid 19 in Gyn cancer patients 

Gyn Oral Abstracts #ASCO22 #gyncsm Beeghly-Fadiel
COVID-19 in patients with gyn cancer: preliminary rpt from the COVID-19 and Cancer Consortium (CCC19).
Retrospective cohort
Characteristicof those with severe covid - Age, black race , high comorbidities pic.twitter.com/5ye8ZneFnC

— Dee Sparacio (@womenofteal) June 6, 2022

Thank you Dr Shannon Westin for tweeting from the session. 

Next up  Addressing Challenges in Ovarian Cancer Management. 

Dee

Every Day is a Blessing!